JY BioMed ADC Technology Wins Innovation Award, Eyes Global Licensing. Taiwan's JY BioMed has earned the 22nd National Innovation Award for its HCAb-ADC platform, secured FDA Orphan Drug Designation for pancreatic cancer, and published findings in Cancer Letters, as it advances international licensing partnerships across lung, pancreatic, and colorectal cancers.

🌸 Week 2 Mother's Day Challenge — Win Another Premium Skincare Gift! 🎉 Friends who joined last week, listen up! You have another chance this week to win a bottle from the iV Angel Angel Series, sponsored by YC Biotech 🌟 Limited quantities — while supplies last! Join us in celebrating the moms who mean the world to us. 🌸

Celebrate Mother's Day with JY BioMed and YC Biotech! Complete simple social media tasks to win a premium iV Angel skincare gift — serum or cream valued up to NT$5,280. Limited quantities available. Campaign runs April 30 – May 4. Don't miss out!

JY BioMed announces dual FDA Type II Drug Master File acceptance in January 2025, covering UC-MSC and UC-MSC-derived Exosomes. Establishing a fully traceable, vertically integrated regulatory platform, JY BioMed is advancing toward IND submission and positioning as an early leader in the exosome therapeutics space.

Discover how Dr. Ethan Shen, Founder & Chairman of JY BioMed, merges spiritual practice with biotech innovation — driven by a vow to advance cancer immunotherapy research in Taiwan and beyond.

From a small pharmacy in Wanhua, Dr. Ethan Shen led JY BioMed into cell therapy and regenerative medicine—advancing biotech innovation and new possibilities in cancer treatment.